Cargando…
Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy
Melittin, the principal constituent in bee venom, is an attractive candidate for cancer therapy. However, its clinical applications are limited by hemolysis, nonspecific cytotoxicity, and rapid metabolism. Herein, a novel genetically engineered vesicular antibody‐melittin (VAM) drug delivery platfor...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658496/ https://www.ncbi.nlm.nih.gov/pubmed/38023709 http://dx.doi.org/10.1002/btm2.10482 |
_version_ | 1785137430488154112 |
---|---|
author | Zhang, Jianzhong Liu, Xue Xia, Yutian Xu, Shuyu Liu, Xuan Xiao, Haiqing Wang, Xiaoyong Liu, Chao Liu, Gang |
author_facet | Zhang, Jianzhong Liu, Xue Xia, Yutian Xu, Shuyu Liu, Xuan Xiao, Haiqing Wang, Xiaoyong Liu, Chao Liu, Gang |
author_sort | Zhang, Jianzhong |
collection | PubMed |
description | Melittin, the principal constituent in bee venom, is an attractive candidate for cancer therapy. However, its clinical applications are limited by hemolysis, nonspecific cytotoxicity, and rapid metabolism. Herein, a novel genetically engineered vesicular antibody‐melittin (VAM) drug delivery platform was proposed and validated for targeted cancer combination therapy. VAM generated from the cellular plasma membrane was bio‐synthetically fabricated, with the recombinant protein (hGC33 scFv‐melittin) being harbored and displayed on the cell membrane. The bioactive and targetable nanomelittin conjugated by hGC33 scFv could be released in an MMP14‐responsive manner at tumor sites, which reduced off‐target toxicity, especially the hemolytic activity of melittin. Importantly, VAM could be loaded with small‐molecule drugs or nanoparticles for combination therapy. Nanomelittin formed pores in membranes and disturbed phospholipid bilayers, which allowed the anticancer agents (i.e., chemotherapeutic drug doxorubicin and sonosensitizer purpurin 18 nanoparticles) co‐delivered by VAM to penetrate deeper tumor sites, leading to synergistic therapeutic effects. In particular, the punching effect generated by sonodynamic therapy further improved the immunomodulatory effect of nanomelittin to activate the immune response. Taken together, our findings indicate that clinically translatable VAM‐based strategies represent a universal, promising approach to multimodal synergetic cancer therapy. |
format | Online Article Text |
id | pubmed-10658496 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106584962023-01-04 Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy Zhang, Jianzhong Liu, Xue Xia, Yutian Xu, Shuyu Liu, Xuan Xiao, Haiqing Wang, Xiaoyong Liu, Chao Liu, Gang Bioeng Transl Med Special Issue Articles Melittin, the principal constituent in bee venom, is an attractive candidate for cancer therapy. However, its clinical applications are limited by hemolysis, nonspecific cytotoxicity, and rapid metabolism. Herein, a novel genetically engineered vesicular antibody‐melittin (VAM) drug delivery platform was proposed and validated for targeted cancer combination therapy. VAM generated from the cellular plasma membrane was bio‐synthetically fabricated, with the recombinant protein (hGC33 scFv‐melittin) being harbored and displayed on the cell membrane. The bioactive and targetable nanomelittin conjugated by hGC33 scFv could be released in an MMP14‐responsive manner at tumor sites, which reduced off‐target toxicity, especially the hemolytic activity of melittin. Importantly, VAM could be loaded with small‐molecule drugs or nanoparticles for combination therapy. Nanomelittin formed pores in membranes and disturbed phospholipid bilayers, which allowed the anticancer agents (i.e., chemotherapeutic drug doxorubicin and sonosensitizer purpurin 18 nanoparticles) co‐delivered by VAM to penetrate deeper tumor sites, leading to synergistic therapeutic effects. In particular, the punching effect generated by sonodynamic therapy further improved the immunomodulatory effect of nanomelittin to activate the immune response. Taken together, our findings indicate that clinically translatable VAM‐based strategies represent a universal, promising approach to multimodal synergetic cancer therapy. John Wiley & Sons, Inc. 2023-01-04 /pmc/articles/PMC10658496/ /pubmed/38023709 http://dx.doi.org/10.1002/btm2.10482 Text en © 2023 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Special Issue Articles Zhang, Jianzhong Liu, Xue Xia, Yutian Xu, Shuyu Liu, Xuan Xiao, Haiqing Wang, Xiaoyong Liu, Chao Liu, Gang Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy |
title | Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy |
title_full | Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy |
title_fullStr | Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy |
title_full_unstemmed | Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy |
title_short | Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy |
title_sort | genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy |
topic | Special Issue Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658496/ https://www.ncbi.nlm.nih.gov/pubmed/38023709 http://dx.doi.org/10.1002/btm2.10482 |
work_keys_str_mv | AT zhangjianzhong geneticallyengineerednanomelittinvesiclesformultimodalsynergeticcancertherapy AT liuxue geneticallyengineerednanomelittinvesiclesformultimodalsynergeticcancertherapy AT xiayutian geneticallyengineerednanomelittinvesiclesformultimodalsynergeticcancertherapy AT xushuyu geneticallyengineerednanomelittinvesiclesformultimodalsynergeticcancertherapy AT liuxuan geneticallyengineerednanomelittinvesiclesformultimodalsynergeticcancertherapy AT xiaohaiqing geneticallyengineerednanomelittinvesiclesformultimodalsynergeticcancertherapy AT wangxiaoyong geneticallyengineerednanomelittinvesiclesformultimodalsynergeticcancertherapy AT liuchao geneticallyengineerednanomelittinvesiclesformultimodalsynergeticcancertherapy AT liugang geneticallyengineerednanomelittinvesiclesformultimodalsynergeticcancertherapy |